Company / Interest Expense
BIOCRYST PHARMACEUTICALS INC Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$108.2M
FY2023
5-year range
$59.3M / $108.2M
FY2019-FY2023
Trend
+9.2%
vs FY2022
Sector context
#10 of 44
Health Care
What the data says
BIOCRYST PHARMACEUTICALS INC's interest expense of $108M is higher than 77% of companies in the Health Care sector (FY2023). Interest Expense has increased for 7 consecutive years, from $6M in FY2016 to $108M in FY2023.
Based on SEC 10-K filings.
$108M in FY2023 with a 5-year CAGR of +63.8%. Top quartile in the Health Care sector.
Increased from $59M to $108M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +95.4%
- 5-Year CAGR
- +63.8%
- 10-Year CAGR
- -
Sector benchmark
-62.8% below sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's interest expense has grown for 7 consecutive years.
- 5-year CAGR of +63.8%, indicating consistent growth.
- In FY2023, interest expense increased 9.2% year-over-year.
- Ranks #10 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $108.2M | +9.2% |
| FY2022 | $99.1M | +67.1% |
| FY2021 | $59.3M | +308.9% |
| FY2020 | $14.5M | +21.9% |
| FY2019 | $11.9M | +29.6% |
| FY2018 | $9.2M | +7.1% |
| FY2017 | $8.6M | +32.0% |
| FY2016 | $6.5M | +24.8% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026